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Conclusions. These class differences between CCBs in theirClass differences in the effects of calcium channel blockers in
relative impact on systemic BP profiles, renal autoregulation,the rat remnant kidney model.
and glomerular pressure transmission may have clinically sig-Background. Controversy persists as to the existence of class
nificant implications and may account for the variable glomeru-differences between calcium channel blockers (CCBs) in their
loprotection that has been observed with these agents in bothability to provide renoprotection and as to potential mecha-
experimental models and in humans.nisms involved.
Methods. Rats with 5/6 renal ablation were left untreated
or received diltiazem, verapamil, or felodipine after the first
week, and the relationship between continuous radiotelemet-
The rat remnant kidney (RK) model, produced byrically measured blood pressure (BP) and glomerulosclerosis
right nephrectomy and segmental infarction of two thirds(GS) was assessed at seven weeks. Additionally, the effects of
these CCBs on renal autoregulation and hypertrophy were of the left kidney, has been extensively used to investi-
examined at three weeks after renal ablation. gate the progressive nature of chronic human renal dis-
Results. Although an excellent linear correlation was ob- ease [1–8]. The initially normal remnant nephrons un-served between the average BP levels and GS in all groups
dergo compensatory increases in size and function, but(r 5 0.75 to 0.84, P , 0.01), significant protection was not
with time, these rats develop a syndrome of hyperten-achieved with any of the CCBs, but for different reasons. The
antihypertensive effects of diltiazem were not sustained beyond sion, proteinuria, and progressive glomerulosclerosis
the second week. Verapamil significantly reduced the average (GS), the pathogenesis of which remains controversial
BP (144 6 4 mm Hg vs. 181 6 8 in untreated rats) but shifted [1–8]. Substantial evidence supports the concept that thethe slope of the relationship between BP and GS (increase in
compensatory vasodilation of the preglomerular vascula-percentage GS/mm Hg increase in average systolic BP) to the
ture and the associated impairment in renal autoregula-left (x intercept 121 vs. 144 mm Hg for untreated rats, P ,
0.01) so that GS was not reduced. Felodipine also significantly tion after an approximate 5/6 renal ablation permit an
reduced the average BP (144 6 3 mm Hg) and shifted the exaggerated transmission of systemic pressure to the glo-
slope to the left (x intercept 123 mm Hg), but additionally
merular capillaries, resulting in glomerular capillary hy-made the slope steeper (2.3 6 0.5 vs. 0.82 6 0.2 in untreated
pertension and injury [2, 3, 5, 8, 9]. Essentially identicalrats). Because of these differing effects on the relationship
between BP and GS, the rank order of GS for any given BP mechanisms have also been postulated to play a major
elevation was as follows: felodipine . verapamil . diltia- role in the progression of diabetic renal disease [9–15].
zem 5 untreated. Felodipine, but not verapamil or diltiazem, The well-documented adverse effects of systemic hyper-caused additional impairment of the already impaired renal
tension in accelerating the progression of chronic renalautoregulation in untreated rats, thereby explaining its adverse
disease regardless of etiology is consistent with such aeffects on GS. By contrast, the adverse effects of verapamil
on GS were attributable to the greater amplitude of BP fluctu- concept [16–20]. As a logical extension of this concept,
ations that was observed in the verapamil-treated rats such the use of antihypertensive agents has become a primary
that for any given average BP, these rats were exposed to
therapeutic strategy to slow the rate of nephron loss.greater peak pressures as compared with the other groups.
However, antihypertensives are not uniformly protec-None of the CCBs had a significant effect on glomerular hyper-
trophy. tive. Substantial controversy persists as to the success of
individual antihypertensive agents other than angioten-
sin-converting enzyme inhibitors in achieving such reno-Key words: glomerulosclerosis, nephrectomy, hypertrophy, blood pres-
sure, hypertension, telemetry, renoprotection. protection [21–25]. Evidence is particularly controversial
with calcium channel blockers (CCBs), with beneficial,Received for publication July 20, 1998
neutral, and even adverse effects having been reportedand in revised form November 23, 1998
Accepted for publication December 29, 1998 [26–34]. Additionally, class differences between CCBs
have been noted in some but not other studies [31–34]. 1999 by the International Society of Nephrology
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The reasons for such conflicting results with CCBs are and dark (18:00 to 6:00 hr) cycle. All rats received food
and water ad libitum throughout the study.not clear, but several possibilities exist.
First, an accurate assessment of the ambient blood pres-
Radiotelemetry studiessure (BP) profiles is a critical prerequisite for a valid com-
parison of the relationship between the relative antihyper- The rats were anesthetized with sodium pentobarbital
(45 mg/kg intraperitoneally), subjected to approximatelytensive and glomeruloprotective efficacies of different
regimens. Rapid, spontaneous, and large BP fluctuations 5/6 renal ablation (right nephrectomy and ligation of all
but one posterior extrarenal branch of the left renalhave been documented by chronic radio-telemetry in
conscious, unrestrained rats (and most other species), artery), and prepared for telemetric monitoring of BP
(Data Sciences International, St. Paul, MN, USA) at theparticularly when hypertension is present [35–39]. Such
BP lability makes it extremely unlikely that the conven- time of the renal ablation surgery as previously described
[30, 36, 37]. Each rat had a BP sensor (model TA11PA-tional tail-cuff measurements that have been used in
most of these investigations can either assess the overall C40; Data Sciences International) inserted intraperito-
neally. The sensor’s catheter was inserted into the aortapressure burden with sufficient accuracy or can ensure
equivalent ambient systemic BP profiles to allow valid below the level of the renal arteries, and the radio fre-
quency transmitter was fixed to the peritoneum. Thecomparisons between different regimens. Therefore,
some of the reported differences in glomeruloprotection rats were housed individually in plastic cages that were
placed on top of the receiver. The signals from the pres-achieved by CCBs despite “equivalent” BP control may,
in fact, be due to BP differences that are not detected sure sensor were converted, temperature compensated,
and sent via the radio frequency transmitter to the telem-by the conventional tail-cuff method [30, 37].
Second, CCBs can have adverse effects on renal auto- etry receiver. The receiver was connected to a BCM-100
consolidation matrix, which transmitted the informationregulation, allowing a greater transmission of systemic
BP and its fluctuations to the renal microvasculature to the Dataquest IV acquisition system (Data Sciences
International). Systolic BP (SBP) in each animal was[40–42]. Consistent with such an interpretation, we have
continuously recorded at 10-minute intervals for approx-recently reported that the dihydropyridine CCB nifedi-
imately seven weeks. Tail vein blood samples were ob-pine further impairs the already compromised autoregu-
tained at three days for measurement of serum creatininelatory ability of RKs [30] and alters the relationship
(SCr) as an index of the degree of renal mass reductionbetween BP and GS such that a greater degree of GS is
[30]. At approximately seven days, the rats were ran-observed for any given BP in nifedipine-treated rats as
domly assigned to the untreated group or received diltia-compared with untreated animals. It is possible that class
zem (750 to 1500 mg/liter of drinking water), verapamildifferences exist between CCBs in the severity of their
(750 mg/liter of drinking water), or felodipine (0.1% byadverse effects on renal autoregulation, which may result
weight in standard rat chow). The felodipine chow wasin differences in glomeruloprotection. Finally, CCBs
kept covered with aluminum foil to prevent photodegra-have been reported to have significant growth effects
dation. In the case of diltiazem, the rats were initiallyin the RK model, and a reduction in the glomerular
started on 750 mg/liter of drinking water. The amounthypertrophy response has been postulated to contribute
of diltiazem was increased to 1000 to 1500 mg/liter into the glomeruloprotection provided by these agents in
8 of 10 rats over the first few days in this group becausesome studies [29, 34, 43]. It is possible that the differential
of a poor initial antihypertensive response. After seveneffects of CCBs on GS in the RK model may reflect
weeks, tail vein SCr and 24-hour urine collections fordifferences in their respective “antigrowth” effects on
protein excretion were obtained. The rats were thenglomerular hypertrophy.
anesthetized with intravenous sodium pentobarbital (40These studies were undertaken to examine if class
mg/kg). A tracheostomy was performed using polyethyl-differences exist between CCBs in their ability to protect
ene (PE-200) tubing, and the rats were surgically pre-against GS in the RK model and whether BP-dependent
pared for clearance studies as described previously [30,or BP-independent mechanisms account for such differ-
44]. In brief, a carotid artery was cannulated with PE-ences. The following classes of CCBs were investigated:
50 tubing and connected to a Windograf (model 40-8474;the benzothiazepine (diltiazem), the phenylalkylamine
Gould Inc., Glen Burnie, MD, USA) for continuous re-(verapamil), and the dihydropyridine (felodipine).
cording of mean arterial pressure (AP). A femoral vein
was cannulated with PE-50 tubing, and a priming dose
METHODS of inulin in 150 mm NaCl was administered, followed
Two sets of investigations were performed on male by a continuous maintenance infusion of 150 mm NaCl
Sprague-Dawley rats (body wt 200 to 300 g) that were containing inulin at 0.055 ml/min to maintain the plasma
fed a standard protein diet (Purina, St. Louis, MO, USA) concentration of inulin at approximately 50 mg/dl and
for replacement of surgical and ongoing fluid losses. Theand synchronized to a 12:12 hour light (6:00 to 18:00 hr)
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left ureter was then cannulated with polyethylene tubing one kidney section for each animal was measured using
a digitizing pad, as described previously [30, 45]. Thefor collection of urine samples. A 1.0 mm R series flow
probe (Transonic Systems Inc., Ithaca, NY, USA) was mean glomerular volume (VG) was then calculated from
the respective mean AG as VG 5 b/k (AG3/2), where b 5placed around the left renal artery for measurement of
renal blood flow (RBF) by a flowmeter (Transonic Sys- 1.38 is the size distribution coefficient and k 5 1.1 is the
shape coefficient for glomeruli idealized as spheres [46].tems Inc.), as described previously [30, 44]. At the con-
clusion of the surgery, a 150 mm NaCl bolus equal to
Analyses, calculations, and statistics1% of the body weight was administered. Two 20-minute
clearances of inulin were obtained. Blood samples were Urinary protein was measured by the quantitative sul-
fosalicylic acid method, with human serum albumin serv-obtained at the midpoint of each urine collection. At the
conclusion of these studies, the rats were killed, and the ing as the standard. Serum creatinine was measured using
a creatinine analyzer (Beckman Instruments Inc., Fuller-kidneys were harvested for morphological studies.
ton, CA, USA) [30, 36, 37]. Inulin in urine and plasma
Autoregulatory studies filtrates was determined spectrophotometrically by the
diphenylamine method, as described previously [3, 36,Rats assigned to the autoregulatory studies underwent
renal ablation without implantation of radiotransmitters 44]. GFR was calculated using standard formulae. RPP
was calculated as the mean AP 2 renal venous pressureand were followed for three weeks without radioteleme-
try. At approximately seven days, the rats were randomly (assigned a value of 5 mm Hg). Renal vascular resistance
was calculated as RPP (mm Hg)/RBF (ml/min/kg). Auto-assigned to receive either no treatment (U) or diltiazem,
verapamil, or felodipine as in the radiotelemetry studies. regulatory index (AI) was calculated by the method of
Semple and de Wardener [47] as follows: AI 5 [(RBF2 2The dose of diltiazem used was 1000 mg/liter of drinking
water for these studies. After three weeks, the rats were RBF1)/RBF1]/[RPP2 2 RPP1)/RPP1]. An AI of zero indi-
cates perfect autoregulation, whereas an AI of one indi-anesthetized with intravenous sodium pentobarbital (40
mg/kg) and surgically prepared as described earlier here. cates that the vessels act as passive conduits for blood
flow [47]. All results are expressed as mean 6 se. Statisti-After the measurement of RBF and glomerular filtration
rate (GFR) at the ambient mean arterial pressures cal analysis was performed using analysis of variance,
followed by Student–Newman–Keuls test or by Kriskall–(APs), RBF autoregulatory studies were performed us-
ing aortic miniclamps positioned above and below the Wallis nonparametric analysis of variance, followed by
Dunn’s multiple comparison test, as appropriate [48].left renal artery to raise or lower renal perfusion pressure
(RPP) as previously described [30, 44]. The RBF was Linear regression analysis was used to calculate the
slopes and intercepts of the relationship between BP andallowed to stabilize for one to two minutes at each pres-
sure before RBF measurements were made. At the con- GS in each group. Analysis of covariance was used to
compare the slopes and intercepts between the groupsclusion of these studies, the rats were killed, and the
kidneys were harvested for morphological and morpho- using the Minitab Software package (Minitab Inc., State
College, PA, USA) [48]. A P value of less than 0.05 wasmetric studies.
considered statistically significant.
Morphologic methods
Transverse sections of the kidney through the papilla
RESULTS
were fixed in situ by perfusion for five minutes at the
Radiotelemetry studiesmeasured BP with 1.25% glutaraldehyde in 0.1 m caco-
dylate buffer. Sections were cut at a thickness of 2 mm Table 1 shows that the initial body weight, SCr, and
24-hour urine protein excretion for the four groups wereand were stained with hematoxylin and eosin and peri-
odic acid-Schiff. Sections were evaluated systematically not significantly different from each other. Similarly, the
SCr at three days was not significantly different betweenin each kidney for glomerular injury (segmental sclero-
sis) in a blinded fashion by standard morphologic meth- the groups, indicating comparable renal mass reduction
in all groups. Although the diltiazem- and felodipine-ods [3, 30, 36, 37]. At least 100 glomeruli in each animal
were evaluated, and the severity of glomerulosclerosis treated rats tended to gain less weight as a group, because
of the large interanimal variability in each group, neitherwas expressed as the percentage of glomeruli exhibiting
such injury. the difference in weight gain nor the final body weight
were statistically significant. Similarly, the kidney weights
Morphometric methods at seven weeks were also not significantly different be-
tween the four groups. Measurements of GFR, RBF,Glomerular volume was measured by area perimeter
analysis (Bioquant System IV software; R&M Biomet- and RVR during the clearance studies also failed to
reveal any significant differences.rics Inc., Nashville, TN, USA). The cross-sectional area
(AG) of 75 consecutive glomerular profiles contained in Figure 1 illustrates the course of the 24-hour averages
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Table 1. Functional data for the radiotelemetry studies
Initial Final z7 weeks
Body wt D wt GFR RBF
Body wt SCr Proteinuria 3 days SCr AP RVR
N g mg/dl mg/24 hrs mg/dl g mm Hg mm Hg/(ml /min /kg) ml /min /kg
Untreated 11 25665 0.3 60.04 3 60.3 0.960.05 427623 171 622 153 610 6.961.3 3.060.4 25 63
Diltiazem 10 26166 0.3 60.03 3 60.3 0.860.08 384631 123 626 168 610 7.160.8 2.560.5 25 63
Verapamil 12 25164 0.3 60.03 4 60.9 0.760.04 430615 179 616 127 69a 4.860.6 2.660.4 28 62
Felodipine 11 25066 0.3 60.02 3 60.5 0.760.08 391616 141 616 116 68a 5.761.3 2.360.5 24 63
a P , 0.05 compared to untreated or diltiazem-treated rats
Fig. 2. Overall average blood pressure (BP) during the first seven days
and during the subsequent approximate six weeks in 5/6 renal ablated
rats that after the seventh day were left untreated (h; N 5 11), or
Fig. 1. Course of systolic blood pressure (BP; 24-hr averages) over received diltiazem (750 to 1500 mg/liter of drinking water; ; N 5 10),
approximately seven weeks in the four groups. All rats underwent a verapamil (750 mg/liter of drinking water; ; N 5 12), or felodipine
5/6 renal ablation (right nephrectomy 1 infarction of approximately (0.1% by weight in chow; j; N 5 11). BP was radiotelemetrically
two thirds of the left kidney). After 7 days, the rats were left untreated recorded continuously at 10-minute intervals, starting at 6 p.m. on the
(h; N 5 11) or received diltiazem (750 to 1500 mg/liter of drinking day of renal ablation surgery to sacrifice approximately seven weeks
water; j; N 5 10), verapamil (750 mg/liter of drinking water; .; N 5 later. *P , 0.01 vs. first week, dP , 0.01 vs. untreated and diltiazem.
12), felodipine mixed in diet (0.1%; H; N 5 11) by weight in chow.
Blood pressure (BP) was radiotelemetrically recorded continuously at
10-minute intervals, starting at 6 p.m. on the day of renal ablation
surgery to sacrifice approximately seven weeks later.
of the average SBP during the first week before the
initiation of treatment and during the following approxi-
mately six weeks (Fig. 2). The average SBP during the
first week was not significantly different between theof SBP after approximate 5/6 renal ablation in untreated
animals and in the three groups treated with CCBs. For groups. There was no significant change in the average
SBP in the untreated and diltiazem-treated rats duringthe first seven days after renal ablation and before the
initiation of antihypertensive therapy, the BP was similar the subsequent six weeks. By contrast, both verapamil
and felodipine caused a significant reduction in the aver-in the four groups. There was an initial reduction in BP
with all three treatment regimens. However, the antihy- age SBP during the final approximate six weeks as com-
pared with their respective BP during the first week.pertensive effect of diltiazem was modest and transient.
By the end of the third week after renal ablation (the Additionally, the average SBP of verapamil- and felodip-
ine-treated animals was significantly lower than that ofsecond week after the initiation of therapy), no differ-
ences could be observed in the systolic BP of the diltia- the untreated and diltiazem-treated animals during the
final six weeks, but was not significantly different fromzem-treated group from that of the untreated animals.
By contrast, BP was significantly lower throughout the each other. Figure 3 A and D illustrate the course of
telemetric SBP recordings at 10-minute intervals in a ratcourse in the verapamil- and felodipine-treated animals,
although some decrease in the antihypertensive effec- from each of the four groups. Figure 3A graphically
displays the spontaneous fluctuations of SBP in an un-tiveness of these agents was also observed over the time
course of the studies. The differences between the four treated rat. The BP fluctuation pattern was not altered
by diltiazem or felodipine (Fig. 3 B and D); however,groups are summarized and illustrated by a comparison
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Fig. 3. Illustrations of the course of systolic
blood pressure (BP) recorded every 10 min-
utes for approximately seven weeks in a rat
with an approximate 5/6 renal ablation from
each of the four groups: (A) untreated, (B)
diltiazem, (C) verapamil, and (D) felodipine.
verapamil-treated rats exhibited an exaggerated ampli- This difference is quantitatively shown in Figure 4C, in
which the standard deviations are plotted as a percentagetude of BP fluctuations, as illustrated in Figure 3C. This
difference in the pattern of BP fluctuations is more of the average SBP. As can be noted, this parameter
was significantly increased by verapamil treatment.clearly illustrated by the decompressed 24-hour segments
of BP recordings of the rats treated with verapamil (Fig. The protein excretion rate (mg/24 hr) and the percent-
age of glomeruli exhibiting GS in the RKs of these four4A) and felodipine (Fig. 4B). As can be noted, the vera-
pamil-treated rats exhibited greater peak increases in groups after approximately seven weeks of radioteleme-
try are presented in Figure 5. There were no statisticallySBP occurring cyclically at one- to three-hour intervals.
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Fig. 3. Continued.
significant differences in proteinuria and GS between the average SBP during the final approximate six weeks was
compared between the four groups, significant differ-four groups, although both proteinuria and GS tended to
be the greatest in felodipine-treated rats. A direct and ences were observed. The slope of this relationship be-
tween GS and SBP in untreated rats, that is, the increasestrong relationship between the average SBP and GS
was observed in each of the individual four groups, with in percentage of GS/mm Hg increase in average SBP
(0.82 6 0.2), was not significantly altered by diltiazemcorrelation coefficients ranging between 0.75 and 0.84
(Fig. 6). However, when the relationship of GS to the (0.81 6 0.2). Verapamil treatment did not significantly
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Fig. 4. (A) A decompressed 24-hour segment from the blood pressure
(BP) recording shown in Figure 3C in a rat treated with verapamil.
The mean SBP 6 sd for the 24 hours was 124.4 6 14.2 mm Hg, with
16% of the 144 readings being more than 140 mm Hg. (B) A similar
decompressed segment from the BP recording shown in Figure 3D in
a rat treated with felodipine. The mean SBP 6 sd for the 24 hours was
124.3 6 5.2 mm Hg, with none of the BP readings being more than 140
mm Hg. (C) The standard deviations expressed as a percentage of the
overall average SBP, an index of the amplitude of BP fluctuations are
shown for each of the four groups during the first week (before therapy)
and during the subsequent six weeks (after therapy). Symbols are: (h)
N 5 11 untreated; ( ) N 5 10 diltiazem; ( ) N 5 12 verapamil; (j)
N 5 11 felodipine.
alter the slope per se (1.1 6 0.3), but did result in a
significant shift to the left as indicated by the significantly
different x intercept for the verapamil group (121 mm
Hg) as compared with the untreated rats (143 mm Hg,
P , 0.01). By contrast, felodipine not only caused a
significant shift to the left of the slope (x intercept 123
mm Hg, P , 0.01 versus untreated) but additionally
caused it to be much steeper (2.3 6 0.5 increase in per-
centage GS/mm Hg increase in average SBP, P , 0.01
vs. each of the other three groups). These changes in the
slopes of the relationship between BP and GS resulted in
GS, which was greatest in the felodipine-treated rats, and
lowest in the diltiazem-treated rats, with the verapamil-
treated rats exhibiting an intermediate degree of GS for
any given BP elevation.
Fig. 5. Proteinuria and percentage of glomerular injury at the end of
approximately 7 weeks in the four groups of rats with approximate 5/6 Autoregulatory studies
renal ablation who were left untreated (h; N 5 11), received diltiazem
No significant differences were present for the initial( ; N 5 10), verapamil ( ; N 5 12), or felodipine (j; N 5 11) after
the first week. body weight, SCr, and 24-hour protein excretion rates in
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Fig. 6. (A) Correlations of the percentage of glomeruli with sclerosis at approximately 7 weeks in individual rats with ablation from all four
groups with their average systolic BP during the final six weeks (the mean of all approximately 6000 BP readings obtained radiotelemetrically
every 10 minutes after the first week). After the first seven days, the rats had received no treatment, diltiazem, verapamil, or felodipine. (B) Linear
regression analysis of the slopes of the relationship between the average BP during the final six weeks and percentage GS for each of the four
groups of rats with 5/6 renal ablation who received no treatment, diltiazem, verapamil or felodipine after approximately seven days. Symbols are:
(h) untreated (N 5 11; r 5 0.82, slope 0.82 6 0.2, x intercept 143 mm Hg); (j) diltiazem (N 5 10; r 5 0.81 slope 0.86 6 0.2, x intercept 137 mm
Hg); (.) verapamil (N 5 12; r 5 0.75, slope 1.08 6 0.3, x intercept 121 mm Hg); (H) felodipine (N 5 11; r 5 0.84, slope 2.3 6 0.5, x intercept
123 mm Hg). P for the correlation coefficient for each group , 0.002. The slope for the felodipine group was significantly different from the slopes
of all other groups (P , 0.01). The intercepts for the verapamil-treated and felodipine-treated groups were significantly different than that of the
untreated or diltiazem-treated groups (P , 0.01). There were no significant differences between the untreated and diltiazem-treated groups.
Table 2. Functional and structural data for the autoregulatory studies
Baseline Final z3 weeks
RBF GFR
Body wt SCr 3 days SCr Body wt AP RVR Kidney wt Glom vol
N g mg/dl mg/dl g mm Hg mm Hg/(ml /min /kg) g lm23 31026ml /min /kg
Untreated 12 24867 0.4 60.03 0.8 60.06 315615 168 68 9.361.7 23.263.3 2.6 60.2 2.4960.14 2.060.16
Diltiazem 11 24565 0.4 60.03 0.8 60.06 290611 157 65 5.660.7a 30.963.3 2.6 60.3 2.3160.15 1.8460.16
Verapamil 11 24464 0.3 60.03 0.8 60.05 265615 135 67a 5.360.5a 26.061.9 3.1 60.3 2.2660.21 1.8360.12
Felodipine 12 24864 0.3 60.02 0.9 60.07 273611 143 67a 6.360.8a 24.662.1 2.5 60.4 2.3260.08 1.9760.14
a P , 0.05 compared to untreated or diltiazem treated rats
the four groups or rats that underwent autoregulatory shown in Figure 7. All four groups demonstrated signifi-
cant impairment in RBF autoregulation (autoregulatorystudies (Table 2). Serum creatinine at three days was
also not significantly different between the four groups, indices of more than 0.4). The autoregulatory ability was
impaired to a similar degree in control, diltiazem-, andindicating comparable renal mass reduction as in the
radiotelemetry studies. Table 2 also shows that the final verapamil-treated rats, as indicated by the lack of sig-
nificant differences in the autoregulatory indices forbody weight, RK weight, and glomerular volume at three
weeks were not significantly different between the four these groups. By contrast, felodipine administration re-
sulted in significant additional impairment in RBF auto-groups. Differences were also not observed in the RBF
and GFR measurements performed at ambient BP be- regulatory responses, as indicated by the significantly
higher autoregulatory indices in this group as comparedfore autoregulatory studies. However, in contrast to the
RVR values at seven weeks, RVR was significantly lower with the other three groups (P , 0.01). In fact, the
autoregulatory indices of approximately one observedat three weeks in all of the CCB-treated groups as com-
pared with untreated rats. The difference in RVR be- in the felodipine group indicate a complete loss of auto-
regulatory ability and a resultant passive behavior oftween individual CCB-treated groups was not statisti-
cally significant. resistance vessels in this group. Calculation of RVR
changes during the autoregulatory studies confirmed thisThe results of the RBF autoregulation studies are
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on the systemic BP and its relationship to GS. We have
previously demonstrated that GS in untreated individual
rats with 5/6 renal ablation exhibits an exceedingly close
linear relationship to their radiotelemetrically measured
average SBP [36, 37]. We have therefore suggested that
the impact of an antihypertensive agent on the slope of
this relationship between BP and GS may provide a
more valid method to separate the agent’s BP-dependent
and BP-independent effects on GS [30, 37]. If a given
antihypertensive agent reduces both BP and GS but does
not significantly alter the slope of the relationship be-
tween BP and GS from that observed in untreated ani-
mals, the glomeruloprotection can be ascribed primarily
to its BP-dependent (antihypertensive) effects [37]. BP-
independent protection by an antihypertensive agent
would be expected to reduce the slope and/or shift it to
Fig. 7. Renal blood flow (RBF) autoregulatory studies in the four the right, while BP-independent deleterious effects on
groups of rats that underwent an approximate 5/6 renal ablation three GS would be manifested by a shift of the slope to the
weeks before. After day 7, the rats were left untreated (h), received
left or the slope becoming more steep [30].diltiazem (j), verapamil (.), or felodipine (H). Graded changes in
renal perfusion pressure (RPP) were produced by aortic miniclamp and Our studies provide further support for this concept.
resulted in significant changes in RBF with every change in RPP in all There was an excellent correlation between BP and GS
groups (P , 0.01, repeated means analysis of variance). The bottom
in each of the experimental groups (r 5 0.75 to 0.84),of the figure shows the calculated autoregulatory indices (AI) for the
changes in RBF for perfusion pressure changes between 150 and 100 indicating the marked BP dependence of glomerular in-
mm Hg. An AI of 0 indicates perfect autoregulation, whereas an AI of jury in this model, even in treated rats. However, signifi-
approximately 1.0 indicates resistance vessels acting as passive conduits
cant class differences were observed between the threewithout autoregulatory responses. The AI for RPP changes for the two
changes in RPP were not significantly different from each other; therefore, CCBs in the dosages used in their effect on the systemic
a single AI for the RBF change between (150 to 100 mm Hg) is pre- BP, as well as on the relationship between BP and GS.
sented. The AI was significantly greater in felodipine-treated rats com-
Because of the very transient antihypertensive effects ofpared with each of the other three groups (* P , 0.05 maximum).
diltiazem, the overall pressure burden was not signifi-
cantly reduced, despite dosages that were twofold to
fourfold greater than those reported to be antihyperten-
finding, with the felodipine-treated rats exhibiting no sive in other rat models [49, 50] and tended to reduce
growth. This relative antihypertensive ineffectivenesssignificant change in RVR during the change in pressure
may reflect differences in the pathogenesis of systemicfrom 140 to 100 mm Hg (the mean RVR at approximately
hypertension between these models. Additionally, diltia-100 mm Hg was 94% of the value at 140 mm Hg). By
zem also failed to alter the relationship between BPcontrast, a significant fall in RVR was observed in the
and GS, indicating a lack of significant BP-independentother three groups, with the mean RVR values at approx-
effects of this agent in this model. By contrast, in theimately 100 mm Hg, averaging 81, 78, and 82% in the
dosages used, both verapamil and felodipine resulted inuntreated, diltiazem-treated and verapamil-treated rats,
significant and comparable reduction of the daily averagerespectively.
SBP. Despite this antihypertensive effectiveness, both
verapamil and felodipine failed to provide significant
DISCUSSION glomeruloprotection because of their concurrent adverse
A large body of experimental and clinical evidence effects on the slope of the relationship between average
supports the importance of BP control in slowing the BP and GS. In the case of verapamil, the slope per se
seemingly inexorable progression of both diabetic and was not changed, but it was shifted to the left, indicating
nondiabetic renal disease [4, 9, 16–20]. Despite their not only that a greater degree of GS was observed at
antihypertensive effectiveness and wide clinical usage, any given average SBP, but also that BP would need to
the renoprotective ability of individual CCBs remains be reduced to lower levels to provide complete glomeru-
controversial [23–34]. These studies show that none of loprotection in verapamil-treated animals. By contrast,
the three major classes of CCBs were able to provide felodipine not only caused a similar shift to the left of
glomeruloprotection in the 5/6 renal ablation model of the slope of the relationship between BP and GS, but
progressive GS. However, the mechanisms responsible additionally made it significantly steeper. Consequently,
for this failure were different for each of the three CCBs a given increase in BP resulted in a disproportionally
greater increase in GS in felodipine-treated animals asand stemmed from the class differences in their effects
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compared with all other groups, including verapamil. effects of felodipine on renal autoregulation [57–60].
Given the spontaneous, large, and frequent BP fluctua-These similar, yet different, adverse effects of verapamil
and felodipine on the relationship between BP and GS tions that are observed in these animals in the unanesthe-
tized state, the efficiency of the renal autoregulatorysuggest that both CCBs had BP-independent deleterious
effects on GS that were likely mediated through separate responses is likely to be the primary determinant of the
degree to which such fluctuations are transmitted to glo-mechanisms.
Among the potential BP-independent mechanisms merular capillaries [30, 38, 39]. Therefore, a complete
loss of this protective mechanism, as observed in thethat have been postulated to be pathogenetically signifi-
cant in the RK model, the glomerular hypertrophy felodipine-treated animals, is expected to greatly exag-
gerate the glomerular capillary exposure to systemic hy-(growth) response has been suggested by several investi-
gators to be of major importance [6, 7, 29, 51, 52]. The pertension with resultant increased GS, as was observed.
In contrast to felodipine, the adverse effects of vera-precise cellular mechanisms have not yet been defini-
tively established, but both an increase in glomerular pamil on the relationship between BP and GS are not
explained by additional deleterious effects on renal auto-capillary wall tension through the Laplace Law effects
(tension 5 pressure 3 radius) and an increase in the regulation. It is possible that the shift in the slope to the
left of the relationship between average BP and GS isactivity of pathogenetic growth factors associated with
the glomerular hypertrophy response have been postu- a consequence of the fact that animals treated with vera-
pamil exhibit a greater amplitude of BP fluctuations aslated [6, 7, 51–53]. The present data do not show that
differences in glomerular hypertrophy play a significant compared with the untreated and felodipine-treated rats.
Therefore, for any given average BP, the glomerularrole in CCB-treated animals, as none of the CCBs had
a significant effect on glomerular hypertrophy. capillaries in verapamil-treated rats may have been ex-
posed to higher peak pressures. If valid, such an interpre-Differential effects on the relationship between BP
and GS may also result from differential effects of antihy- tation would suggest that differences in BP fluctuation
patterns in addition to the average SBP may need topertensive agents on renal autoregulation. Normally, the
autoregulatory vasoconstrictor responses of the preglo- be taken into account when comparing the effects of
antihypertensive agents on glomerular injury. To ourmerular vasculature provide the primary protection
against increases in systemic pressure (episodic or sus- knowledge, such a change in BP fluctuation patterns by
verapamil or other antihypertensive agents has not beentained) from being transmitted to glomerular capillaries
[3, 8, 16, 38, 39]. These autoregulatory responses have described previously. The mechanism(s) responsible re-
mains to be identified. Verapamil is known to have addi-been demonstrated to be impaired in RKs, although
the precise mechanisms remain undefined [3, 8]. Normal tional effects possibly unrelated to calcium channel
blockade, such as an alteration of sympathetic activity,autoregulatory vasoconstriction in response to pressure
increases is believed to be mediated by calcium entry which may have contributed to the change in the BP
fluctuation patterns [58, 61]. Whether such an effect oc-through voltage-gated, “L”-type calcium channels as a
result of stretch (pressure)-induced depolarization [54– curs in other species (humans) is not known.
Although the verapamil preparation used in these56]. Consistent with such a mechanism, acute administra-
tion of all three classes of CCBs has been shown to studies was not a long-acting formulation, the short-act-
ing nature of the preparation is unlikely to account forimpair renal autoregulation in intact kidneys of both
normotensive and hypertensive rats [40–42]. The reason the observed frequency pattern of BP fluctuations (one-
to three-hr cycles throughout the day). In this context,that felodipine, but not diltiazem or verapamil during
chronic administration, had an additional deleterious im- it is of note that the effects of felodipine, a long-acting
dihydropyridine CCB, on BP fluctuation patterns, renalpact on the already impaired renal autoregulation in
rats with RKs remains to be defined. Although all three autoregulation, and GS are very similar to that pre-
viously observed by us with nifedipine, a short-actingclasses of CCBs exert their effects through blocking the
“L”-type, voltage-gated channels, differences in binding dihydropyridine CCB [30]. These data, therefore, do not
support the suggestion that the potentially deleteriousaffinity have been demonstrated, depending on the rela-
tive state of activity of the calcium channel [57–60]. renal effects of CCB may only be particular to the short-
acting CCB preparations, as has been suggested for ad-Moreover, although all three classes of CCBs bind to
the a1 subunit of the “L”-type calcium channel, they bind verse cardiovascular events [62–65]. Although it is also
not yet clear if the potentially adverse renal and cardiacto different and discrete sites of the channel protein,
with probably specific structure–function relationships effects are both mediated by similar mechanisms, it is of
interest that the recent concerns about possible adverse[57–60]. The dihydropyridine CCBs bind to a site that
is very proximate to the putative transmembrane voltage cardiovascular effects of CCBs have also primarily been
directed at the dihydropyridine CCBs.sensor segment (S4) of the a1 subunit of the calcium
channel, and this may account for the greater adverse In summary, our data demonstrate that none of three
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